SCHEMBL23104873

SCHEMBL23104873

CCCC(=O)N[C@H]1C(O)O[C@@H](COC(=O)CCC(=O)OC[C@H]2OC(O)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGB P11216 2/20 0.48
▸ SLC2A1 P11166 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ TLR4 O00206 2/20 0.37
▸ AMDHD2 Q9Y303 1/20 0.37
▸ PTGS1 P23219 2/20 0.37
▸ PTGS2 P35354 2/20 0.37
▸ HK1 P19367 3/20 0.36
▸ HK2 P52789 3/20 0.36
▸ GAA P10253 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ PRKD3 O94806 1/20 0.34
▸ PRKCG P05129 1/20 0.34
▸ PRKCB P05771 1/20 0.34
▸ PRKCA P17252 1/20 0.34
▸ PRKCH P24723 1/20 0.34
▸ PRKCI P41743 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21138044 1.00 PYGB (0.48) PYGBSLC2A1KDM4ELMNACYP2D6
SCHEMBL21137953 0.96 PYGB (0.45) PYGBSLC2A1KDM4ELMNACYP2D6
SCHEMBL21138039 0.94 PYGB (0.45) PYGBSLC2A1KDM4ELMNACYP2D6
SCHEMBL21137986 0.91 PYGB (0.41) PYGBKDM4ELMNACYP2D6CYP2C19
SCHEMBL31353005 0.88 TLR4 (0.44) PYGBTLR4
SCHEMBL21137910 0.88 TLR4 (0.44) PYGBTLR4
SCHEMBL21137960 0.87 PYGB (0.40) PYGBSLC2A1KDM4ELMNACYP2D6
SCHEMBL21137917 0.87 PYGB (0.40) PYGBSLC2A1KDM4ELMNACYP2D6
SCHEMBL21138114 0.87 PYGB (0.40) PYGBSLC2A1KDM4ELMNACYP2D6
Hydrochloric Acid SCHEMBL31353008 0.86 PYGB (0.41) PYGBSLC2A1KDM4ELMNACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, GLA PYGB 760/4885SLC2A1 34/4885KDM4E 3760/4885
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA PYGB 760/4885SLC2A1 34/4885KDM4E 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback